SCHEMBL692824

SCHEMBL692824

CS(=O)(=O)N1CCN(S(=O)(=O)c2cc(C#N)ccc2Oc2cc(Cl)cc(Cl)c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
KMT2A Q03164 2/20 0.45
TBXA2R P21731 3/20 0.44
EPAS1 Q99814 9/20 0.42
VEGFA P15692 1/20 0.42
KDM4E B2RXH2 2/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
CNR1 P21554 1/20 0.41
TRPV4 Q9HBA0 2/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
TSHR P16473 2/20 0.40
PKM P14618 1/20 0.40
USP2 O75604 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15197155 0.94 TBXA2R (0.43) ALDH1A1KMT2ATBXA2REPAS1VEGFA
SCHEMBL13679842 0.89 ALDH1A1 (0.58) ALDH1A1KMT2ATBXA2RKDM4EPOLB
SCHEMBL13413623 0.89 ALDH1A1 (0.58) ALDH1A1KMT2ATBXA2RKDM4EPOLB
SCHEMBL1279869 0.88 CNR1 (0.44) ALDH1A1KMT2ATBXA2RKDM4EPOLB
SCHEMBL13157486 0.88 ALDH1A1 (0.46) ALDH1A1KMT2ATBXA2REPAS1VEGFA
SCHEMBL2824037 0.88 KMT2A (0.49) ALDH1A1KMT2ATBXA2REPAS1VEGFA
SCHEMBL693683 0.88 TBXA2R (0.45) KMT2ATBXA2RKDM4ETSHRPKM
SCHEMBL12693452 0.87 ALDH1A1 (0.48) ALDH1A1KMT2ATBXA2REPAS1VEGFA
SCHEMBL694148 0.87 ALDH1A1 (0.49) ALDH1A1KMT2ATBXA2REPAS1KDM4E
SCHEMBL1279160 0.87 TBXA2R (0.46) ALDH1A1KMT2ATBXA2REPAS1VEGFA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2502921-B1 Arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS INC (US) 2015-05-20 EP disclosed
US-8658642-B2 Arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2014-02-25 US disclosed
US-20130217687-A1 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2013-08-22 US disclosed
US-8420639-B2 Arylsulfonamide CCR3 antagonists AXIKIN PHARMACEUTICALS, INC. (US) 2013-04-16 US disclosed
EP-2502921-A1 Arylsulfonamide CCR3 antagonists Axikin Pharmaceuticals, Inc. (US) 2012-09-26 EP disclosed
EP-2502921-A1 Arylsulfonamide CCR3 antagonists Axikin Pharmaceuticals, Inc. (US) 2012-09-26 EP disclosed
EP-2421838-A2 ARYLSULFONAMIDE CCR3 ANTAGONISTS Axikin Pharmaceuticals, Inc. (US) 2012-02-29 EP disclosed
US-20100273795-A1 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2010-10-28 US disclosed
WO-2010123960-A2 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2010-10-28 WO disclosed
WO-2010123960-A2 ARYLSULFONAMIDE CCR3 ANTAGONISTS AXIKIN PHARMACEUTICALS, INC. (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273795-A1 ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 ALDH1A1 2454/4885KMT2A 2688/4885TBXA2R 2704/4885
US-20130217687-A1 ARYLSULFONAMIDE CCR3 ANTAGONISTS CCR3, CCR1, CCR4 ALDH1A1 2454/4885KMT2A 2688/4885TBXA2R 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.